|
JP5688877B2
(ja)
|
2005-11-11 |
2015-03-25 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
癌疾患の治療用キナゾリン誘導体
|
|
NZ779754A
(en)
|
2009-01-16 |
2023-04-28 |
Exelixis Inc |
Malate salt of n-(4-{ [6,7-bis(methyloxy)quinolin-4-yl] oxy} phenyl)-n’-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
|
|
MA33208B1
(fr)
|
2009-03-25 |
2012-04-02 |
Genentech Inc |
Anticorps anti-fgfr3 et procédés d'utilisation de ceux-ci
|
|
PT2451445T
(pt)
|
2009-07-06 |
2019-07-10 |
Boehringer Ingelheim Int |
Processo para secagem de bibw2992, dos seus sais e de formulações farmacêuticas sólidas compreendendo este ingrediente ativo
|
|
TW201106972A
(en)
*
|
2009-07-27 |
2011-03-01 |
Genentech Inc |
Combination treatments
|
|
WO2011014872A2
(en)
*
|
2009-07-31 |
2011-02-03 |
The Johns Hopkins University |
Compositions and methods for diagnosing, treating or preventing neoplasias
|
|
UA108618C2
(uk)
|
2009-08-07 |
2015-05-25 |
|
Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
|
|
EP2896632B1
(en)
*
|
2009-11-13 |
2017-10-25 |
Daiichi Sankyo Europe GmbH |
Material and methods for treating or preventing HER-3 associated diseases
|
|
EA030435B1
(ru)
|
2010-07-16 |
2018-08-31 |
Экселиксис, Инк. |
ТАБЛЕТКА, СОДЕРЖАЩАЯ МОДУЛЯТОР c-MET В ФОРМЕ КРИСТАЛЛИЧЕСКОЙ L-МАЛАТНОЙ СОЛИ (ВАРИАНТЫ), СПОСОБ ЕЕ ПРОИЗВОДСТВА И СПОСОБ ЛЕЧЕНИЯ ОНКОЛОГИЧЕСКОГО ЗАБОЛЕВАНИЯ С ЕЕ ИСПОЛЬЗОВАНИЕМ
|
|
AU2011290672B2
(en)
|
2010-08-20 |
2015-07-09 |
Novartis Ag |
Antibodies for epidermal growth factor receptor 3 (HER3)
|
|
TW201302793A
(zh)
|
2010-09-03 |
2013-01-16 |
Glaxo Group Ltd |
新穎之抗原結合蛋白
|
|
MX352926B
(es)
|
2010-09-27 |
2017-12-14 |
Exelixis Inc |
Inhibidores dobles de met y factor de crecimiento endotelial vascular (vegf) para el tratamiento de cancer de prostata resistente a la castracion y metastasis osteoblasticas en los huesos.
|
|
SG191230A1
(en)
*
|
2010-12-23 |
2013-07-31 |
Nestec Sa |
Drug selection for malignant cancer therapy using antibody-based arrays
|
|
CN102532109B
(zh)
*
|
2010-12-27 |
2015-05-13 |
浙江海正药业股份有限公司 |
一种拉帕替尼及其盐的合成方法
|
|
CN102093421B
(zh)
*
|
2011-01-28 |
2014-07-02 |
北京康辰药业有限公司 |
一种含磷取代基的喹啉类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
|
|
BR112013020362A2
(pt)
|
2011-02-10 |
2018-05-29 |
Exelixis Inc |
processos para a preparação de compostos de quinolina, compostos e combinações farmacêuticas que os contem
|
|
US20120252840A1
(en)
|
2011-04-04 |
2012-10-04 |
Exelixis, Inc. |
Method of Treating Cancer
|
|
MX2013012695A
(es)
*
|
2011-05-02 |
2014-03-27 |
Exelixis Inc |
Metodo para el tratamiento del cancer y el dolor por cancer de hueso.
|
|
EP2758057B1
(en)
|
2011-09-22 |
2017-05-31 |
Exelixis, Inc. |
Method for treating osteoporosis
|
|
CN104395284A
(zh)
|
2011-10-20 |
2015-03-04 |
埃克塞里艾克西斯公司 |
制备喹啉衍生物的方法
|
|
SG11201402004YA
(en)
*
|
2011-11-14 |
2014-05-29 |
Cephalon Inc |
Uracil derivatives as axl and c-met kinase inhibitors
|
|
EP3590538A1
(en)
*
|
2011-12-05 |
2020-01-08 |
Novartis AG |
Antibodies for epidermal growth factor receptor 3 (her3)
|
|
TWI594986B
(zh)
|
2011-12-28 |
2017-08-11 |
Taiho Pharmaceutical Co Ltd |
Antineoplastic agent effect enhancer
|
|
DK2810937T3
(en)
|
2012-01-31 |
2017-03-13 |
Daiichi Sankyo Co Ltd |
PYRIDONE DERIVATIVES
|
|
WO2013166296A1
(en)
|
2012-05-02 |
2013-11-07 |
Exelixis, Inc. |
A dual met - vegf modulator for treating osteolytic bone metastases
|
|
CN103664879A
(zh)
*
|
2012-09-17 |
2014-03-26 |
杨育新 |
一类治疗创伤性脑损伤疾病的化合物及其用途
|
|
CN103705521A
(zh)
*
|
2012-09-28 |
2014-04-09 |
韩冰 |
一类治疗脑梗塞的化合物及其用途
|
|
WO2014093750A1
(en)
*
|
2012-12-14 |
2014-06-19 |
Glaxosmithkline Llc |
Method of administration and treatment
|
|
CA2907334C
(en)
|
2013-03-15 |
2021-12-07 |
Exelixis, Inc. |
Metabolites of n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
|
|
KR102060540B1
(ko)
|
2013-04-03 |
2019-12-31 |
삼성전자주식회사 |
항 c-Met 항체 및 항 Ang2 항체를 포함하는 병용 투여용 약학 조성물
|
|
US11564915B2
(en)
|
2013-04-04 |
2023-01-31 |
Exelixis, Inc. |
Cabozantinib dosage form and use in the treatment of cancer
|
|
TWI649308B
(zh)
|
2013-07-24 |
2019-02-01 |
小野藥品工業股份有限公司 |
喹啉衍生物
|
|
BR112016008125B1
(pt)
|
2013-10-14 |
2023-11-21 |
Janssen Biotech, Inc. |
Domínio proteico isolado de fibronectina tipo iii modificado com cisteína, seu método de produção e método para produzir uma molécula isolada de de fibronectina tipo iii biespecífica modificada com cisteína
|
|
US11045468B2
(en)
|
2014-02-04 |
2021-06-29 |
Astellas Pharma Inc. |
Pharmaceutical composition comprising diamino heterocyclic carboxamide compound as active ingredient
|
|
BR112016018450A2
(pt)
|
2014-02-14 |
2018-09-18 |
Exelixis Inc |
formas sólidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida, processos de preparo e métodos de uso
|
|
EP3119476A1
(en)
|
2014-03-17 |
2017-01-25 |
Exelixis, Inc. |
Dosing of cabozantinib formulations
|
|
EP3125935B1
(en)
|
2014-04-03 |
2019-10-23 |
Merck Patent GmbH |
Combinations of cancer therapeutics
|
|
KR102223502B1
(ko)
|
2014-05-09 |
2021-03-05 |
삼성전자주식회사 |
항 c-Met/항 EGFR/항 Her3 다중 특이 항체 및 이의 이용
|
|
TWI723572B
(zh)
|
2014-07-07 |
2021-04-01 |
日商第一三共股份有限公司 |
具有四氫吡喃基甲基之吡啶酮衍生物及其用途
|
|
EP3174854B1
(en)
|
2014-07-31 |
2022-08-24 |
Exelixis, Inc. |
Method of preparing fluorine-18 labeled cabozantinib and its analogs
|
|
MX382904B
(es)
|
2014-08-05 |
2025-03-13 |
Exelixis Inc |
Combinaciones de fármacos para tratar mieloma múltiple.
|
|
ES2749726T3
(es)
|
2014-12-25 |
2020-03-23 |
Ono Pharmaceutical Co |
Derivado de quinolina
|
|
FR3039401B1
(fr)
*
|
2015-07-31 |
2018-07-13 |
Les Laboratoires Servier |
Nouvelle association entre le 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione et un inhibiteur de la tyr kinase du egfr
|
|
CN106467541B
(zh)
*
|
2015-08-18 |
2019-04-05 |
暨南大学 |
取代喹诺酮类衍生物或其药学上可接受的盐或立体异构体及其药用组合物和应用
|
|
EP3442531A1
(en)
|
2016-04-15 |
2019-02-20 |
Exelixis, Inc. |
Method of treating renal cell carcinoma using n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluoropheny)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate
|
|
MA45412A
(fr)
|
2016-06-21 |
2021-05-26 |
Janssen Biotech Inc |
Molécules de liaison au domaine de fibronectine de type iii modifiées par la cystéine
|
|
CN107235896B
(zh)
*
|
2016-09-13 |
2019-11-05 |
上海翔锦生物科技有限公司 |
酪氨酸激酶抑制剂及其应用
|
|
CN107235897B
(zh)
*
|
2016-09-27 |
2019-08-16 |
上海翔锦生物科技有限公司 |
酪氨酸激酶抑制剂及其应用
|
|
CN110225770B
(zh)
|
2016-12-14 |
2022-04-26 |
杨森生物科技公司 |
结合cd8a的纤连蛋白iii型结构域
|
|
EP3554535A4
(en)
|
2016-12-14 |
2020-10-21 |
Janssen Biotech, Inc. |
PD-L1 BINDING FIBRONECTIN TYPE III DOMAINS
|
|
EP3554561B1
(en)
|
2016-12-14 |
2023-06-28 |
Janssen Biotech, Inc. |
Cd137 binding fibronectin type iii domains
|
|
TWI779007B
(zh)
|
2017-01-26 |
2022-10-01 |
日商小野藥品工業股份有限公司 |
喹啉衍生物的乙磺酸鹽
|
|
WO2018151177A1
(ja)
|
2017-02-15 |
2018-08-23 |
大鵬薬品工業株式会社 |
医薬組成物
|
|
JP7074760B2
(ja)
|
2017-09-08 |
2022-05-24 |
大鵬薬品工業株式会社 |
抗腫瘍剤及び抗腫瘍効果増強剤
|
|
US11826363B2
(en)
|
2017-10-13 |
2023-11-28 |
Ono Pharmaceutical Co., Ltd. |
Therapeutic agent for solid cancers, which comprises Axl inhibitor as active ingredient
|
|
TWI831259B
(zh)
|
2018-06-15 |
2024-02-01 |
漢達生技醫藥股份有限公司 |
包含達沙替尼十二烷基硫酸鹽組合物的膠囊
|
|
BR112021014504A2
(pt)
*
|
2019-01-25 |
2021-09-28 |
Exelixis, Inc. |
Compostos para o tratamento de transtornos dependentes de cinase
|
|
WO2021076543A1
(en)
|
2019-10-14 |
2021-04-22 |
Aro Biotherapeutics Company |
Epcam binding fibronectin type iii domains
|
|
US11781138B2
(en)
|
2019-10-14 |
2023-10-10 |
Aro Biotherapeutics Company |
FN3 domain-siRNA conjugates and uses thereof
|
|
CN119119240A
(zh)
|
2019-10-14 |
2024-12-13 |
Aro生物疗法公司 |
结合cd71的纤维粘连蛋白iii型结构域
|
|
CN115073367A
(zh)
*
|
2021-03-16 |
2022-09-20 |
南京科默生物医药有限公司 |
一种用作axl抑制剂的抗肿瘤化合物及其用途
|
|
EP4323008A4
(en)
|
2021-04-14 |
2026-02-25 |
Aro Biotherapeutics Company |
FN3-ARNSI DOMAIN CONJUGATES AND THEIR USES
|
|
CA3214552A1
(en)
|
2021-04-14 |
2022-10-20 |
Russell C. Addis |
Cd71 binding fibronectin type iii domains
|
|
WO2024163400A1
(en)
|
2023-01-31 |
2024-08-08 |
Handa Oncology, Llc |
Improved cabozantinib compositions and methods of use
|